SB 271046

Drug Profile

SB 271046

Alternative Names: SB 271046-A

Latest Information Update: 07 Jan 2004

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator GlaxoSmithKline
  • Class Antidepressants; Antipsychotics; Nootropics; Sulfonamides; Thiophenes
  • Mechanism of Action Serotonin 6 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Alzheimer's disease; Schizophrenia

Most Recent Events

  • 15 Dec 2003 Discontinued - Phase-I for Alzheimer's disease in United Kingdom (PO)
  • 15 Dec 2003 Discontinued - Phase-I for Schizophrenia in United Kingdom (PO)
  • 16 Aug 2002 A preclinical study has been added to the Psychotic Disorders pharmacodynamics section
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top